metformin has been researched along with Coronary Artery Disease in 56 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Coronary Artery Disease: Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study aimed to evaluate the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin on the biomarkers of inflammation, thrombosis, and atherosclerosis in T2DM patients with symptomatic coronary artery disease (CAD)." | 9.34 | Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease. ( Kabel, M; Mostafa, T; Omran, G; Shokry, A; Werida, R, 2020) |
| " We investigated the effect of liraglutide combined with metformin on LGI and lipoprotein density profiles in patients with stable coronary artery disease (CAD) and newly diagnosed T2DM." | 9.30 | Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial. ( Anholm, C; Fenger, M; Haugaard, SB; Kristiansen, OP; Kumarathurai, P; Madsbad, S; Nielsen, OW; Pedersen, LR; Sajadieh, A; Samkani, A; Walzem, RL, 2019) |
| "Metformin treatment significantly reduced LVMI, LVM, office systolic BP, body weight, and oxidative stress." | 9.30 | A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial. ( Al-Talabany, S; Baig, F; Bhalraam, U; Choy, AM; Gandy, SJ; George, J; Houston, JG; Hussain, MS; Khan, F; Lang, CC; Matthew, S; McKinnie, A; Mohan, M; Mordi, IR; Singh, JSS; Struthers, AD, 2019) |
| "Forty-one patients with type 2 diabetes and stable coronary artery disease were randomized to receive liraglutide or placebo to a backbone therapy of metformin in this double-blind, placebo-controlled 12 along with 12 weeks crossover study." | 9.24 | Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double-blind, placebo-controlled, crossover study. ( Anholm, C; Fabricius-Bjerre, A; Haugaard, SB; Kristiansen, O; Kumarathurai, P; Madsbad, S; Nielsen, OW; Sajadieh, A, 2017) |
| " The diabetic medication, Metformin, reduces IR and aids weight loss and may therefore regress LVH." | 9.20 | Metformin and its effects on myocardial dimension and left ventricular hypertrophy in normotensive patients with coronary heart disease (the MET-REMODEL study): rationale and design of the MET-REMODEL study. ( Baig, F; Lang, CC; McSwiggan, S; Mohan, M; Rutherford, L, 2015) |
| " We compared the long-term effects of glipizide and metformin on the major cardiovascular events in type 2 diabetic patients who had a history of coronary artery disease (CAD)." | 9.17 | Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. ( Cui, L; Dong, Y; Hong, J; Lai, S; Li, H; Liu, C; Lv, A; Ning, G; Shen, J; Shen, W; Su, Q; Tang, W; Wang, D; Wang, W; Wu, G; Zhang, Y; Zhao, J; Zhou, Z; Zhu, D; Zou, D, 2013) |
| "GDF-15 was not associated with type 2 diabetes, glycaemic traits, CAD risk factors or colorectal cancer." | 6.90 | The impact of GDF-15, a biomarker for metformin, on the risk of coronary artery disease, breast and colorectal cancer, and type 2 diabetes and metabolic traits: a Mendelian randomisation study. ( Au Yeung, SL; Luo, S; Schooling, CM, 2019) |
| "Patients with type 2 diabetes present with an accelerated atherosclerotic process." | 6.84 | The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study. ( Eskenazi, D; Fisman, EZ; Goldenberg, I; Goldkorn, R; Klempfner, R; Leor, J; Naftali-Shani, N; Tenenbaum, A; Younis, A, 2017) |
| "Metformin, the drug of first choice in type 2 diabetes mellitus (T2DM), reduces cardiovascular (CV) morbidity and mortality in part independently of improved glycemic control and changes in traditional risk factors." | 6.80 | Differential associations of circulating asymmetric dimethylarginine and cell adhesion molecules with metformin use in patients with type 2 diabetes mellitus and stable coronary artery disease. ( Chyrchel, B; Golay, A; Kruszelnicka, O; Surdacki, A, 2015) |
| "Newly diagnosed type 2 diabetes mellitus (T2DM) in patients with coronary artery disease (CAD) more than doubles the risk of death compared with otherwise matched glucose tolerant patients." | 6.79 | Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol. ( Anholm, C; Haugaard, SB; Klit, MS; Kristiansen, OP; Kumarathurai, P; Ladelund, S; Madsbad, S; Nielsen, OW; Sajadieh, A, 2014) |
| "Metformin has a better effect of reducing the incidence of CV events than sulfonylureas." | 6.61 | Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. ( Gao, P; Han, Y; Liu, Y; Shen, Z; Xie, H; Yang, X, 2019) |
| " Logistic regression showed that d, L, different therapeutic agents, and dosage groups were independent risk factors of ISR." | 5.72 | Treatment effect of metformin combined with atorvastatin in reducing in-stent restenosis after percutaneous coronary intervention in coronary artery disease patients with type 2 diabetic patients. ( Chen, M; Li, M; Liu, S; Ma, F; Su, B; Wang, C; Yuan, L; Zhang, S; Zhang, Y; Zheng, Q, 2022) |
| " Methods and Results The Diabetes Prevention Program was a randomized controlled trial comparing an intensive lifestyle intervention, metformin, or placebo for prevention of type 2 diabetes among patients with prediabetes." | 5.69 | Coronary Artery Calcium and Cognitive Decline in the Diabetes Prevention Program Outcomes Study. ( Crandall, JP; Dabelea, D; Gadde, KM; Goldberg, RB; Ibebuogu, UN; Luchsinger, JA; Orchard, TJ; Pi-Sunyer, FX; Schlögl, M; Temprosa, M; Watson, KE; Yin, X, 2023) |
| " This study aimed to evaluate the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin on the biomarkers of inflammation, thrombosis, and atherosclerosis in T2DM patients with symptomatic coronary artery disease (CAD)." | 5.34 | Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease. ( Kabel, M; Mostafa, T; Omran, G; Shokry, A; Werida, R, 2020) |
| "Metformin treatment significantly reduced LVMI, LVM, office systolic BP, body weight, and oxidative stress." | 5.30 | A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial. ( Al-Talabany, S; Baig, F; Bhalraam, U; Choy, AM; Gandy, SJ; George, J; Houston, JG; Hussain, MS; Khan, F; Lang, CC; Matthew, S; McKinnie, A; Mohan, M; Mordi, IR; Singh, JSS; Struthers, AD, 2019) |
| " We investigated the effect of liraglutide combined with metformin on LGI and lipoprotein density profiles in patients with stable coronary artery disease (CAD) and newly diagnosed T2DM." | 5.30 | Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial. ( Anholm, C; Fenger, M; Haugaard, SB; Kristiansen, OP; Kumarathurai, P; Madsbad, S; Nielsen, OW; Pedersen, LR; Sajadieh, A; Samkani, A; Walzem, RL, 2019) |
| "Metformin use does not impair endothelial healing of DES in patients with both insulin- and noninsulin-treated diabetes mellitus." | 5.27 | In Vivo Evaluation of the Synergic Effect of Metformin and mTOR Inhibitors on the Endothelial Healing of Drug-eluting Stents in Diabetic Patients. ( Alfonso, F; Cequier, Á; Cubero-Gallego, H; Ferreiro, JL; Gómez-Hospital, JA; Gómez-Lara, J; Gracida, M; Jiménez-Quevedo, P; Montanya, E; Pinar, E; Romaguera, R; Roura, G; Sabaté, M; Tebé-Codorni, C; Teruel, L, 2018) |
| " We examined the effect of the GLP-1 RA liraglutide on HRV and diurnal variation of HR in overweight patients with newly diagnosed type 2 diabetes (T2D) and stable coronary artery disease (CAD)." | 5.24 | Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study. ( Anholm, C; Haugaard, SB; Kristiansen, O; Kumarathurai, P; Larsen, BS; Madsbad, S; Nielsen, OW; Olsen, RH; Sajadieh, A, 2017) |
| "Forty-one patients with type 2 diabetes and stable coronary artery disease were randomized to receive liraglutide or placebo to a backbone therapy of metformin in this double-blind, placebo-controlled 12 along with 12 weeks crossover study." | 5.24 | Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double-blind, placebo-controlled, crossover study. ( Anholm, C; Fabricius-Bjerre, A; Haugaard, SB; Kristiansen, O; Kumarathurai, P; Madsbad, S; Nielsen, OW; Sajadieh, A, 2017) |
| " The diabetic medication, Metformin, reduces IR and aids weight loss and may therefore regress LVH." | 5.20 | Metformin and its effects on myocardial dimension and left ventricular hypertrophy in normotensive patients with coronary heart disease (the MET-REMODEL study): rationale and design of the MET-REMODEL study. ( Baig, F; Lang, CC; McSwiggan, S; Mohan, M; Rutherford, L, 2015) |
| " We compared the long-term effects of glipizide and metformin on the major cardiovascular events in type 2 diabetic patients who had a history of coronary artery disease (CAD)." | 5.17 | Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. ( Cui, L; Dong, Y; Hong, J; Lai, S; Li, H; Liu, C; Lv, A; Ning, G; Shen, J; Shen, W; Su, Q; Tang, W; Wang, D; Wang, W; Wu, G; Zhang, Y; Zhao, J; Zhou, Z; Zhu, D; Zou, D, 2013) |
| "The aim of the present study was to assess the risk of overall mortality, coronary artery disease (CAD), and congestive heart failure (CHF) in patients with type 2 diabetes mellitus (T2DM) treated with metformin (MF) and an additional antidiabetic agent." | 3.83 | Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic. ( Kannan, S; Karafa, M; Matsuda, S; Pantalone, KM; Wells, BJ; Zimmerman, RS, 2016) |
| "GDF-15 was not associated with type 2 diabetes, glycaemic traits, CAD risk factors or colorectal cancer." | 2.90 | The impact of GDF-15, a biomarker for metformin, on the risk of coronary artery disease, breast and colorectal cancer, and type 2 diabetes and metabolic traits: a Mendelian randomisation study. ( Au Yeung, SL; Luo, S; Schooling, CM, 2019) |
| "Metformin may protect against coronary atherosclerosis in prediabetes and early diabetes mellitus among men." | 2.84 | Effect of Long-Term Metformin and Lifestyle in the Diabetes Prevention Program and Its Outcome Study on Coronary Artery Calcium. ( Aroda, VR; Barrett-Connor, E; Bluemke, DA; Budoff, M; Crandall, JP; Dabelea, D; Goldberg, RB; Horton, ES; Mather, KJ; Orchard, TJ; Schade, D; Temprosa, M; Watson, K, 2017) |
| "Patients with type 2 diabetes present with an accelerated atherosclerotic process." | 2.84 | The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study. ( Eskenazi, D; Fisman, EZ; Goldenberg, I; Goldkorn, R; Klempfner, R; Leor, J; Naftali-Shani, N; Tenenbaum, A; Younis, A, 2017) |
| "Metformin, the drug of first choice in type 2 diabetes mellitus (T2DM), reduces cardiovascular (CV) morbidity and mortality in part independently of improved glycemic control and changes in traditional risk factors." | 2.80 | Differential associations of circulating asymmetric dimethylarginine and cell adhesion molecules with metformin use in patients with type 2 diabetes mellitus and stable coronary artery disease. ( Chyrchel, B; Golay, A; Kruszelnicka, O; Surdacki, A, 2015) |
| "Newly diagnosed type 2 diabetes mellitus (T2DM) in patients with coronary artery disease (CAD) more than doubles the risk of death compared with otherwise matched glucose tolerant patients." | 2.79 | Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol. ( Anholm, C; Haugaard, SB; Klit, MS; Kristiansen, OP; Kumarathurai, P; Ladelund, S; Madsbad, S; Nielsen, OW; Sajadieh, A, 2014) |
| "Metformin has displayed definite CV benefits related to AMPK." | 2.61 | AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases. ( Li, J; Li, X; Liu, J; Lu, Q; Ren, D; Rousselle, T; Sun, X; Tong, N, 2019) |
| "Metformin has a better effect of reducing the incidence of CV events than sulfonylureas." | 2.61 | Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. ( Gao, P; Han, Y; Liu, Y; Shen, Z; Xie, H; Yang, X, 2019) |
| "Statins are currently able to stabilize atherosclerotic plaques by lowering plasma cholesterol and pleiotropic effects, but a residual risk for atherosclerotic disease remains." | 2.50 | mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques. ( De Loof, H; De Meyer, GRY; Martinet, W, 2014) |
| "The metabolic syndrome affects 30% of the US population with increasing prevalence." | 2.48 | The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration. ( Hutcheson, R; Rocic, P, 2012) |
| " Logistic regression showed that d, L, different therapeutic agents, and dosage groups were independent risk factors of ISR." | 1.72 | Treatment effect of metformin combined with atorvastatin in reducing in-stent restenosis after percutaneous coronary intervention in coronary artery disease patients with type 2 diabetic patients. ( Chen, M; Li, M; Liu, S; Ma, F; Su, B; Wang, C; Yuan, L; Zhang, S; Zhang, Y; Zheng, Q, 2022) |
| " As stable coronary artery disease (SCAD) patients combined with type 2 diabetes have significantly increased risk for cardiac event, we focused on elucidating the role of microbiota affecting cardiometabolic disease development." | 1.62 | Gut microbiota dysbiosis in stable coronary artery disease combined with type 2 diabetes mellitus influences cardiovascular prognosis. ( Feng, S; Liang, L; Liu, H; Tian, R; Wang, H; Wang, Y; Xing, H; Xu, H; Zhang, S, 2021) |
| "Given the high prevalence of type 2 diabetes mellitus (T2DM) in HT patients, we investigated the association between metformin therapy and cardiovascular outcomes after HT." | 1.51 | Metformin therapy in patients with diabetes mellitus is associated with a reduced risk of vasculopathy and cardiovascular mortality after heart transplantation. ( Amunts, S; Fisman, EZ; Klempfner, R; Lavee, J; Maor, E; Ovdat, T; Peled, Y; Ram, E; Sternik, L; Tenenbaum, A, 2019) |
| "Metformin usage was independently associated with lower CAC scores in T2DM patients." | 1.51 | Association between Metformin Use and Coronary Artery Calcification in Type 2 Diabetic Patients. ( Cai, Z; Chen, Z; Lu, Y; Sun, X; Wang, Y; Wei, J; Weng, T; Xiang, M, 2019) |
| "Metformin was more protective than glyburide for both all-cause (HR: 0." | 1.46 | All-Cause and Cardiovascular Mortality following Treatment with Metformin or Glyburide in Patients with Type 2 Diabetes Mellitus. ( Esteghamati, A; Heidari, B; Larry, M; Mansournia, MA; Nakhjavani, M; Nargesi, AA; Rabizadeh, S; Raee, MR; Zarifkar, M, 2017) |
| "A model that incorporates HbA1c and diabetes complications can serve as a useful clinical decision tool for selection of treatment options." | 1.40 | Second-line agents for glycemic control for type 2 diabetes: are newer agents better? ( Denton, BT; Mason, JE; McCoy, RG; Shah, ND; Smith, SA; Zhang, Y, 2014) |
| "Individuals with type 2 diabetes (T2DM) are at increased risk of cardiovascular disease, including heart failure (HF)." | 1.39 | Metformin treatment may be associated with decreased levels of NT-proBNP in patients with type 2 diabetes. ( Czlonkowski, A; Filipiak, KJ; Kaplon-Cieslicka, A; Opolski, G; Postula, M; Rosiak, M; Trzepla, E, 2013) |
| "Metformin is recommended in type 2 diabetes mellitus because it reduced mortality among overweight participants in the United Kingdom Prospective Diabetes Study when used mainly as a means of primary prevention." | 1.36 | Metformin use and mortality among patients with diabetes and atherothrombosis. ( Bhatt, DL; Goto, S; Marre, M; Pasquet, B; Porath, A; Ravaud, P; Roussel, R; Smith, SC; Steg, PG; Travert, F; Wilson, PW, 2010) |
| "Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride." | 1.35 | Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study. ( Mogensen, CE; Sadikot, SM, 2008) |
| "A total of 2,368 patients with type 2 diabetes and CAD was evaluated." | 1.35 | Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort. ( Jones, TL; Lopes, N; Lu, J; Pop-Busui, R, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.79) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (10.71) | 29.6817 |
| 2010's | 41 (73.21) | 24.3611 |
| 2020's | 8 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M | 1 |
| Ma, F | 1 |
| Su, B | 1 |
| Wang, C | 1 |
| Zheng, Q | 1 |
| Zhang, Y | 5 |
| Li, M | 1 |
| Liu, S | 1 |
| Zhang, S | 2 |
| Yuan, L | 1 |
| Oikonomou, E | 1 |
| Xenou, M | 1 |
| Zakynthinos, GE | 1 |
| Tsaplaris, P | 1 |
| Lampsas, S | 1 |
| Bletsa, E | 1 |
| Gialamas, I | 1 |
| Kalogeras, K | 1 |
| Goliopoulou, A | 1 |
| Gounaridi, MI | 1 |
| Pesiridis, T | 1 |
| Tsatsaragkou, A | 1 |
| Vavouranakis, M | 1 |
| Siasos, G | 1 |
| Tousoulis, D | 1 |
| Zheng, J | 1 |
| Xu, M | 1 |
| Yang, Q | 1 |
| Hu, C | 2 |
| Walker, V | 1 |
| Lu, J | 2 |
| Wang, J | 1 |
| Liu, R | 1 |
| Xu, Y | 1 |
| Wang, T | 1 |
| Zhao, Z | 1 |
| Yuan, J | 1 |
| Burgess, S | 1 |
| Au Yeung, SL | 2 |
| Luo, S | 2 |
| Anderson, EL | 1 |
| Holmes, MV | 1 |
| Smith, GD | 1 |
| Ning, G | 4 |
| Wang, W | 3 |
| Gaunt, TR | 1 |
| Bi, Y | 1 |
| Gadde, KM | 1 |
| Yin, X | 1 |
| Goldberg, RB | 2 |
| Orchard, TJ | 2 |
| Schlögl, M | 1 |
| Dabelea, D | 2 |
| Ibebuogu, UN | 2 |
| Watson, KE | 1 |
| Pi-Sunyer, FX | 1 |
| Crandall, JP | 2 |
| Temprosa, M | 2 |
| Luchsinger, JA | 1 |
| Ram, E | 1 |
| Lavee, J | 1 |
| Tenenbaum, A | 2 |
| Klempfner, R | 2 |
| Fisman, EZ | 2 |
| Maor, E | 1 |
| Ovdat, T | 1 |
| Amunts, S | 1 |
| Sternik, L | 1 |
| Peled, Y | 1 |
| Merino, J | 1 |
| Jablonski, KA | 1 |
| Mercader, JM | 1 |
| Kahn, SE | 1 |
| Chen, L | 1 |
| Harden, M | 1 |
| Delahanty, LM | 1 |
| Araneta, MRG | 1 |
| Walford, GA | 1 |
| Jacobs, SBR | 1 |
| Franks, PW | 1 |
| Knowler, WC | 1 |
| Florez, JC | 1 |
| Werida, R | 1 |
| Kabel, M | 1 |
| Omran, G | 1 |
| Shokry, A | 1 |
| Mostafa, T | 1 |
| Tian, R | 1 |
| Liu, H | 1 |
| Feng, S | 1 |
| Wang, H | 1 |
| Wang, Y | 3 |
| Liang, L | 1 |
| Xu, H | 1 |
| Xing, H | 1 |
| Yeku, OO | 1 |
| Medford, AJ | 1 |
| Fenves, AZ | 1 |
| Uljon, SN | 1 |
| Aroda, VR | 1 |
| Bluemke, DA | 1 |
| Barrett-Connor, E | 1 |
| Budoff, M | 1 |
| Horton, ES | 1 |
| Mather, KJ | 1 |
| Schade, D | 1 |
| Watson, K | 1 |
| Younis, A | 1 |
| Eskenazi, D | 1 |
| Goldkorn, R | 1 |
| Leor, J | 1 |
| Naftali-Shani, N | 1 |
| Goldenberg, I | 1 |
| Njerve, IU | 1 |
| Åkra, S | 1 |
| Weiss, TW | 1 |
| Solheim, S | 1 |
| Øvstebø, R | 1 |
| Aass, HCD | 1 |
| Byrkjeland, R | 1 |
| Arnesen, H | 1 |
| Seljeflot, I | 1 |
| Liu, Y | 2 |
| Jiang, X | 1 |
| Chen, X | 1 |
| Cubero-Gallego, H | 1 |
| Romaguera, R | 1 |
| Gómez-Lara, J | 1 |
| Gómez-Hospital, JA | 1 |
| Sabaté, M | 1 |
| Pinar, E | 1 |
| Gracida, M | 1 |
| Roura, G | 1 |
| Ferreiro, JL | 1 |
| Teruel, L | 1 |
| Tebé-Codorni, C | 1 |
| Jiménez-Quevedo, P | 1 |
| Montanya, E | 1 |
| Alfonso, F | 1 |
| Cequier, Á | 1 |
| Lu, Q | 1 |
| Li, X | 1 |
| Liu, J | 1 |
| Sun, X | 2 |
| Rousselle, T | 1 |
| Ren, D | 1 |
| Tong, N | 1 |
| Li, J | 1 |
| Mohan, M | 2 |
| Al-Talabany, S | 1 |
| McKinnie, A | 1 |
| Mordi, IR | 1 |
| Singh, JSS | 1 |
| Gandy, SJ | 1 |
| Baig, F | 2 |
| Hussain, MS | 1 |
| Bhalraam, U | 1 |
| Khan, F | 1 |
| Choy, AM | 1 |
| Matthew, S | 1 |
| Houston, JG | 1 |
| Struthers, AD | 1 |
| George, J | 1 |
| Lang, CC | 2 |
| Anholm, C | 5 |
| Kumarathurai, P | 5 |
| Samkani, A | 2 |
| Pedersen, LR | 2 |
| Boston, RC | 1 |
| Nielsen, OW | 5 |
| Kristiansen, OP | 3 |
| Fenger, M | 2 |
| Madsbad, S | 5 |
| Sajadieh, A | 5 |
| Haugaard, SB | 5 |
| Schooling, CM | 1 |
| Lu, Y | 1 |
| Weng, T | 1 |
| Chen, Z | 1 |
| Wei, J | 1 |
| Cai, Z | 1 |
| Xiang, M | 1 |
| Rajagopalan, S | 1 |
| Rashid, I | 1 |
| Ziyrek, M | 1 |
| Kahraman, S | 1 |
| Ozdemir, E | 1 |
| Dogan, A | 1 |
| Walzem, RL | 1 |
| Han, Y | 1 |
| Xie, H | 1 |
| Gao, P | 1 |
| Yang, X | 1 |
| Shen, Z | 1 |
| Bajuk Studen, K | 1 |
| Jensterle Sever, M | 1 |
| Pfeifer, M | 1 |
| Rosiak, M | 1 |
| Postula, M | 1 |
| Kaplon-Cieslicka, A | 1 |
| Trzepla, E | 1 |
| Czlonkowski, A | 1 |
| Filipiak, KJ | 1 |
| Opolski, G | 1 |
| Lund, SS | 1 |
| Gong, Y | 1 |
| Hong, J | 3 |
| Lai, S | 3 |
| Martinet, W | 1 |
| De Loof, H | 1 |
| De Meyer, GRY | 1 |
| McCoy, RG | 1 |
| Mason, JE | 1 |
| Smith, SA | 1 |
| Shah, ND | 1 |
| Denton, BT | 1 |
| Lankin, V | 1 |
| Konovalova, G | 1 |
| Tikhaze, A | 1 |
| Shumaev, K | 1 |
| Kumskova, E | 1 |
| Viigimaa, M | 1 |
| Zeng, J | 1 |
| Lv, A | 2 |
| Su, Q | 2 |
| Dong, Y | 2 |
| Zhou, Z | 2 |
| Tang, W | 2 |
| Zhao, J | 2 |
| Cui, L | 2 |
| Zou, D | 2 |
| Wang, D | 2 |
| Li, H | 2 |
| Liu, C | 2 |
| Wu, G | 2 |
| Shen, J | 2 |
| Zhu, D | 2 |
| Shen, W | 2 |
| Xu, G | 1 |
| Klit, MS | 1 |
| Ladelund, S | 1 |
| McSwiggan, S | 1 |
| Rutherford, L | 1 |
| Kruszelnicka, O | 1 |
| Chyrchel, B | 1 |
| Golay, A | 1 |
| Surdacki, A | 1 |
| Kannan, S | 1 |
| Pantalone, KM | 1 |
| Matsuda, S | 1 |
| Wells, BJ | 1 |
| Karafa, M | 1 |
| Zimmerman, RS | 1 |
| Ferrannini, E | 1 |
| DeFronzo, RA | 1 |
| Zonszein, J | 1 |
| Lombardero, M | 1 |
| Ismail-Beigi, F | 1 |
| Palumbo, P | 1 |
| Foucher, S | 1 |
| Groenewoud, Y | 1 |
| Cushing, G | 1 |
| Wajchenberg, B | 1 |
| Genuth, S | 1 |
| Ke, CC | 1 |
| Lai, HC | 1 |
| Lin, CH | 1 |
| Hung, CJ | 1 |
| Chen, DY | 1 |
| Sheu, WH | 1 |
| Lui, PW | 1 |
| Larsen, BS | 1 |
| Olsen, RH | 1 |
| Kristiansen, O | 2 |
| Fabricius-Bjerre, A | 1 |
| Raee, MR | 1 |
| Nargesi, AA | 1 |
| Heidari, B | 1 |
| Mansournia, MA | 1 |
| Larry, M | 1 |
| Rabizadeh, S | 1 |
| Zarifkar, M | 1 |
| Esteghamati, A | 1 |
| Nakhjavani, M | 1 |
| Sadikot, SM | 1 |
| Mogensen, CE | 1 |
| Pop-Busui, R | 1 |
| Lopes, N | 1 |
| Jones, TL | 1 |
| DeVries, JH | 1 |
| Rutter, MK | 1 |
| Nesto, RW | 1 |
| Roussel, R | 1 |
| Travert, F | 1 |
| Pasquet, B | 1 |
| Wilson, PW | 1 |
| Smith, SC | 1 |
| Goto, S | 1 |
| Ravaud, P | 1 |
| Marre, M | 1 |
| Porath, A | 1 |
| Bhatt, DL | 1 |
| Steg, PG | 1 |
| Esposito, K | 1 |
| Maiorino, MI | 1 |
| Di Palo, C | 1 |
| Gicchino, M | 1 |
| Petrizzo, M | 1 |
| Bellastella, G | 1 |
| Saccomanno, F | 1 |
| Giugliano, D | 1 |
| Eurich, DT | 1 |
| Majumdar, SR | 1 |
| McAlister, FA | 2 |
| Tsuyuki, RT | 1 |
| Johnson, JA | 1 |
| Ragia, G | 1 |
| Manolopoulos, VG | 1 |
| Hutcheson, R | 1 |
| Rocic, P | 1 |
| Hanninen, M | 1 |
| Bakal, JA | 1 |
| van Diepen, S | 1 |
| Ezekowitz, JA | 1 |
| CHAKRABARTI, R | 1 |
| HOCKING, ED | 1 |
| FEARNLEY, GR | 1 |
| Kume, A | 1 |
| Miyazaki, T | 1 |
| Daida, H | 1 |
| Anselmino, M | 1 |
| Ohrvik, J | 1 |
| Malmberg, K | 1 |
| Standl, E | 1 |
| Rydén, L | 1 |
| Molavi, B | 1 |
| Rassouli, N | 1 |
| Bagwe, S | 1 |
| Rasouli, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00004992] | Phase 3 | 3,234 participants (Actual) | Interventional | 1996-07-31 | Completed | ||
| The Effect of Adding Vildagliptin Versus Glimepiride to Metformin on Markers of Inflammation, Thrombosis, and Atherosclerosis in Diabetic Patients With Symptomatic Coronary Artery Diseases[NCT03693560] | Phase 4 | 80 participants (Actual) | Interventional | 2018-10-08 | Completed | ||
| Diabetes Prevention Program Outcomes Study[NCT00038727] | Phase 3 | 2,779 participants (Actual) | Interventional | 2002-09-30 | Active, not recruiting | ||
| Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetic Patients With Coronary Artery Disease[NCT01604213] | Phase 4 | 60 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| Efficacy of Metformin as add-on Therapy in Non-Diabetic Heart Failure Patients[NCT05177588] | Phase 4 | 70 participants (Actual) | Interventional | 2021-07-21 | Completed | ||
| Adding Liraglutide to the Backbone Therapy of Biguanide in Patients With Coronary Artery Disease and Newly Diagnosed Type-2 Diabetes[NCT01595789] | Phase 4 | 41 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| MetfoRmin and Its Effects on Myocardial Dimension and Left Ventricular Hypertrophy in Normotensive Patients With Coronary Artery Disease[NCT02226510] | Phase 4 | 68 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes[NCT00006305] | Phase 3 | 2,368 participants (Actual) | Interventional | 2000-09-30 | Completed | ||
| Effect of Metformin Glycinate on Postprandial Lipemia, Glycemic Control and Oxidation Markers in Type 2 Diabetes Patients[NCT02064881] | Phase 2/Phase 3 | 72 participants (Anticipated) | Interventional | 2015-10-31 | Recruiting | ||
| Clinical and Biochemical Study of the Effects of Rosuvastatin, Vitamin E, and N-Acetyl Cysteine on Patients With Non-alcoholic Steatohepatitis: a Randomized Controlled Trial[NCT06105060] | Early Phase 1 | 160 participants (Anticipated) | Interventional | 2023-12-17 | Not yet recruiting | ||
| Markers of Oxidative Stress and Inflammation in Patients With Intestinal Metaplasia and Metabolic Syndrome[NCT02695186] | 180 participants (Anticipated) | Observational | 2016-02-29 | Recruiting | |||
| Phase 4 Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery Disease[NCT00513630] | Phase 4 | 304 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The Prime Study[NCT03031821] | Phase 3 | 168 participants (Actual) | Interventional | 2018-07-12 | Terminated (stopped due to Manufacturer discontinued the production of study drugs.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Primary outcome for years 2002-2008 defined according to American Diabetes Association criteria (fasting plasma glucose level >= 126 mg/dL [7.0 mmol/L] or 2-hour plasma glucose >= 200 mg/dL [11.1 mmol/L], after a 75 gram oral glucose tolerance test (OGTT), and confirmed with a repeat test). (NCT00038727)
Timeframe: Outcomes were assessed from 1996-2008 (approximately 12 years including 6 years of DPP).
| Intervention | diabetes incidence (cases per 100 person (Number) |
|---|---|
| 1 Original Lifestyle | 5.3 |
| 2 Original Metformin | 6.4 |
| 3 Original Placebo | 7.8 |
All cause-mortality through clinic reports and National Death Index search (NCT00038727)
Timeframe: Outcomes were assessed throughout follow-up from 1996 to 2022. National Death Index search conducted in 2019 using early release data as of Dec 2018.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1 Original Lifestyle | 158 |
| 2 Original Metformin | 152 |
| 3 Original Placebo | 143 |
Aggregate microvascular disease is defined as the average prevalence of 3 components: (1) retinopathy measured by photography (ETDRS of 20 or greater); (2) neuropathy detected by Semmes Weinstein 10 gram monofilament, and (3) nephropathy based on estimated glomerular filtration rate (eGFR by chronic kidney disease (CKD-Epi) equation ) (<45 ml/min, confirmed) and albumin-to-creatinine ratio in spot urine (> 30mg/gm, confirmed). (NCT00038727)
Timeframe: Outcomes were assessed from 2012-2013 (approximately 2 years).
| Intervention | average percentage of participants (Number) |
|---|---|
| 1 Original Lifestyle | 11.3 |
| 2 Original Metformin | 13 |
| 3 Original Placebo | 12.4 |
Measured using coronary artery calcification (CAC). (NCT00038727)
Timeframe: Outcomes were assessed from 2012-2013 (approximately 2 years).
| Intervention | CAC geometric mean in AU (Geometric Mean) | |
|---|---|---|
| Men | Women | |
| 1 Original Lifestyle | 70.1 | 6.0 |
| 2 Original Metformin | 40.2 | 6.1 |
| 3 Original Placebo | 63.7 | 5.3 |
(NCT00006305)
Timeframe: five years
| Intervention | participants (Number) |
|---|---|
| Revascularization and Insulin Providing (IP) | 80 |
| Revascularization and Insulin Sensitizing (IS) | 75 |
| Medical Therapy and Insulin Providing (IP) | 80 |
| Medical Therapy and Insulin Sensitizing (IS) | 81 |
(NCT00006305)
Timeframe: five years
| Intervention | participants (Number) |
|---|---|
| Revascularization and Insulin Providing (IP) | 145 |
| Revascularization and Insulin Sensitizing (IS) | 121 |
| Medical Therapy and Insulin Providing (IP) | 143 |
| Medical Therapy and Insulin Sensitizing (IS) | 140 |
9 reviews available for metformin and Coronary Artery Disease
| Article | Year |
|---|---|
Novel Approaches to the Management of Diabetes Mellitus in Patients with Coronary Artery Disease.
Topics: Cardiovascular Diseases; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV | 2023 |
AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases.
Topics: AMP-Activated Protein Kinases; Animals; Coronary Artery Disease; Diabetes Mellitus; Diabetic Cardiom | 2019 |
Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Cause of Death; Coronary Artery Disease; Diabetes Mellitus, | 2019 |
Cardiovascular risk and subclinical cardiovascular disease in polycystic ovary syndrome.
Topics: Adolescent; Adult; Androstenes; Atherosclerosis; Cardiovascular Diseases; Carotid Intima-Media Thick | 2013 |
mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques.
Topics: Absorbable Implants; AMP-Activated Protein Kinases; Animals; Apolipoproteins E; Cholesterol; Clinica | 2014 |
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
Topics: Carbamates; Clinical Trials as Topic; Coronary Artery Disease; Cyclohexanes; Diabetes Mellitus, Type | 2015 |
The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxid | 2012 |
The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxid | 2012 |
The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxid | 2012 |
The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxid | 2012 |
[Treatment for coronary artery disease patients with impaired glucose tolerance].
Topics: Acarbose; Biguanides; Coronary Artery Bypass; Coronary Artery Disease; Glucose Intolerance; Glycosid | 2005 |
A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications.
Topics: Cardiomyopathies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; I | 2007 |
20 trials available for metformin and Coronary Artery Disease
27 other studies available for metformin and Coronary Artery Disease
| Article | Year |
|---|---|
Treatment effect of metformin combined with atorvastatin in reducing in-stent restenosis after percutaneous coronary intervention in coronary artery disease patients with type 2 diabetic patients.
Topics: Atorvastatin; Blood Glucose; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Dia | 2022 |
Efficacy of metformin targets on cardiometabolic health in the general population and non-diabetic individuals: a Mendelian randomization study.
Topics: Coronary Artery Disease; Diabetes Mellitus; Genome-Wide Association Study; Humans; Mendelian Randomi | 2023 |
Metformin therapy in patients with diabetes mellitus is associated with a reduced risk of vasculopathy and cardiovascular mortality after heart transplantation.
Topics: Adult; Cause of Death; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Heart Failure; He | 2019 |
Gut microbiota dysbiosis in stable coronary artery disease combined with type 2 diabetes mellitus influences cardiovascular prognosis.
Topics: Aged; Bacteria; Biomarkers; Case-Control Studies; Clostridiales; Coronary Artery Disease; Diabetes M | 2021 |
Case 15-2021: A 76-Year-Old Woman with Nausea, Diarrhea, and Acute Kidney Failure.
Topics: Acidosis, Lactic; Acute Kidney Injury; Aged; Coronary Artery Disease; Creatinine; Diabetes Mellitus, | 2021 |
Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease.
Topics: Adult; Aged; Blood Glucose; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combin | 2017 |
Association between Metformin Use and Coronary Artery Calcification in Type 2 Diabetic Patients.
Topics: Aged; Calcinosis; Coronary Artery Disease; Coronary Vessels; Cross-Sectional Studies; Diabetes Melli | 2019 |
Regression therapy for cardiovascular disease.
Topics: Cardiovascular Diseases; Coronary Artery Disease; Diabetes Mellitus; Humans; Hypertrophy, Left Ventr | 2019 |
Metformin monotherapy significantly decreases epicardial adipose tissue thickness in newly diagnosed type 2 diabetes patients.
Topics: Adipose Tissue; Body Mass Index; Coronary Artery Disease; Diabetes Mellitus, Type 2; Echocardiograph | 2019 |
Metformin treatment may be associated with decreased levels of NT-proBNP in patients with type 2 diabetes.
Topics: Adrenergic beta-Antagonists; Aged; Atherosclerosis; Biguanides; Cardiovascular Diseases; Coronary Ar | 2013 |
Comment on Hong et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes care 2013;36:1304-1311.
Topics: Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Glipizide; Humans; Male; Metformin | 2014 |
Response to comment on Hong et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes care 2013;36:1304-1311.
Topics: Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Glipizide; Humans; Male; Metformin | 2014 |
Second-line agents for glycemic control for type 2 diabetes: are newer agents better?
Topics: Amputation, Surgical; Blood Glucose; Coronary Artery Disease; Diabetes Complications; Diabetes Melli | 2014 |
The initiation of free radical peroxidation of low-density lipoproteins by glucose and its metabolite methylglyoxal: a common molecular mechanism of vascular wall injure in atherosclerosis and diabetes.
Topics: Adult; Aged; Coronary Artery Disease; Diabetes Mellitus; Female; Glucose; Humans; Lipid Peroxidation | 2014 |
Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic.
Topics: Aged; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug T | 2016 |
Increased Risk of Herpes Zoster in Diabetic Patients Comorbid with Coronary Artery Disease and Microvascular Disorders: A Population-Based Study in Taiwan.
Topics: Adolescent; Adult; Aged; Case-Control Studies; Comorbidity; Coronary Artery Disease; Databases, Fact | 2016 |
All-Cause and Cardiovascular Mortality following Treatment with Metformin or Glyburide in Patients with Type 2 Diabetes Mellitus.
Topics: Aged; Cardiovascular Diseases; Cause of Death; Cohort Studies; Coronary Angiography; Coronary Artery | 2017 |
Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study.
Topics: Adult; Case-Control Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathi | 2008 |
Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort.
Topics: Adult; Aged; Cohort Studies; Coronary Artery Bypass; Coronary Artery Disease; Cross-Sectional Studie | 2009 |
Therapies for type 2 diabetes and coronary artery disease.
Topics: Angioplasty, Balloon, Coronary; Coronary Artery Bypass; Coronary Artery Disease; Diabetes Mellitus, | 2009 |
The BARI 2D study: a randomised trial of therapies for type 2 diabetes and coronary artery disease.
Topics: Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Metformin; | 2010 |
Metformin use and mortality among patients with diabetes and atherothrombosis.
Topics: Age Factors; Aged; Aged, 80 and over; Cerebrovascular Disorders; Coronary Artery Disease; Creatinine | 2010 |
Levels of evidence needed for changing indications, contraindications, and Food and Drug Administration labeling: the case of metformin.
Topics: Canada; Cerebrovascular Disorders; Contraindications; Coronary Artery Disease; Diabetes Mellitus, Ty | 2011 |
Highlights from the latest articles in diabetes pharmacogenomics.
Topics: Cardiovascular Diseases; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; | 2012 |
Neither diabetes nor glucose-lowering drugs are associated with mortality after noncardiac surgery in patients with coronary artery disease or heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Alberta; Angiotensin-Converting Enzyme Inhibit | 2013 |
FIBRINOLYTIC EFFECT OF METFORMIN IN CORONARY-ARTERY DISEASE.
Topics: Arteries; Biomedical Research; Blood Coagulation Tests; Cholesterol; Coronary Artery Disease; Corona | 1965 |
Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart.
Topics: Aged; Blood Glucose; Coronary Artery Disease; Diabetes Mellitus; Diabetic Angiopathies; Drug Therapy | 2008 |